Abstract:Abstract Backgrounds: Tenascin C (TNC) is an extracellular matrix glycoprotein that is abundantly expressed in cancer stroma and its overexpression correlates with tumor progression in various types of cancer including pancreatic adenocarcinoma (PAAD). However, the role of TNC in regards to response to immune checkpoint inhibitor (ICI) still remains to be identified. In this study, we aimed to investigate the potential involvement of TNC in the response to ICI among PAAD patients. Materials and Methods: Transcriptomic profiles were downloaded by TCGA and GTEx database and TNC mRNA levels were compared between tumors and normal tissues. These transcriptomic data were deconvoluted using CIBERSORTx to identify specific enriched pathways in cancer cells and cancer-associated fibroblasts (CAFs) in PAAD patients. Bioinformatic programs were used to predict paracrine communications between cancer cells and cancer-associated fibroblasts (CAFs), and the Tumor Immune Dysfunction and Exclusion (TIDE) score was calculated to predict response to ICI treatment in PAAD patients. An independent immunotherapeutic cohort was applied to validate prediction values for immunotherapy. Results: TNC mRNA levels were significantly upregulated in tumors compared to normal tissues in eight cancer types including PAAD. TNC-high (TNC-H) PAAD patients (n = 138) had significant shorter overall survival than TNC-low (TNC-L) patients (n = 40) (p = 0.0125, Log-rank test). Using CIBERSORTx, TNC was estimated to be predominantly expressed in CAFs in PAAD. In pathway analysis, both cancer cells and CAFs had significant enrichments of the epithelial mesenchymal transition pathway in TNC-H patients. Ligand-receptor interaction analysis showed that TNC produced in CAFs had the highest interaction potentials to bind to integrin families such as ITGαV and ITGβ3 in cancer cells. In an independent immunotherapy data cohort, patients with TNC-H and ITGαV-high or ITGβ3-high expression were associated with poor response to ICI treatment and had shorter overall survival than those with both low expressions. Conclusions: In conclusion, these findings suggest that TNC-high CAFs can play a crucial role in tumor progression and resistance to ICI therapy in PAAD patients, and targeting TNC and its interactions with cancer cells may provide a potential strategy for improving the efficacy of ICI therapy in PAAD. Citation Format: Satoru Furuhashi, Yoshifumi Morita, Akio Matsumoto, Shinya Ida, Ryuta Muraki, Ryo Kitajima, Makoto Takeda, Hirotoshi Kikuchi, Yoshihiro Hiramatsu, Hiroya Takeuchi. Tenascin C in pancreatic cancer-associated fibroblasts enhances epithelial mesenchymal transition and is associated with resistance to immune checkpoint inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1585.

Tenascin-C As a Prognostic Determinant of Colorectal Cancer Through Induction of Epithelial-to-mesenchymal Transition and Proliferation

Characteristics of Primary Cancer Associated Fibroblasts and Normal Fibroblasts and Their Effects on Colorectal Cancer EMT

Tenascin-C Predicts Poor Outcomes for Patients with Colorectal Cancer and Drives Cancer Stemness Via Hedgehog Signaling Pathway

Tenascin C is a Prognostic Determinant and Potential Cancer-Associated Fibroblasts Marker for Breast Ductal Carcinoma

Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer

Tenascin-C Expression is Significantly Associated with the Progression and Prognosis in Gastric GISTs.

Tenascin-C is involved in promotion of cancer stemness via the Akt/HIF1ɑ axis in esophageal squamous cell carcinoma.

CTHRC1 Overexpression Predicts Poor Survival and Enhances Epithelial‐mesenchymal Transition in Colorectal Cancer

Tenascin-C is a diagnostic marker for cervical cancer and a potential marker for cancer-associated fibroblasts in cervical carcinoma

Tenascin-C Expression is Associated with Poor Prognosis in Hepatocellular Carcinoma (HCC) Patients and the Inflammatory Cytokine TNF-α-induced TNC Expression Promotes Migration in HCC Cells.

Tenascin-C, a Prognostic Determinant of Esophageal Squamous Cell Carcinoma.

Tenascin-C as a potential biomarker and therapeutic target for esophageal squamous cell carcinoma

Tenascin-C Induces Resistance to Apoptosis in Pancreatic Cancer Cell Through Activation of ERK/NF-κB Pathway.

Tenascin-C Modulates Cell Cycle Progression to Enhance Tumour Cell Proliferation Through AKT/FOXO1 Signalling in Pancreatic Cancer

Tenascin-C induces migration and invasion through JNK/c-Jun signalling in pancreatic cancer.

Tenascin-C Promotes Bladder Cancer Progression and Its Action Depends on Syndecan-4 and Involves NF-κB Signaling Activation

[Advances in molecular mechanisms of tenascin-C in promoting tumor metastasis].

Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer

Abstract 1585: Tenascin C in pancreatic cancer-associated fibroblasts enhances epithelial mesenchymal transition and is associated with resistance to immune checkpoint inhibitor

The Integrated Pathway of TGFβ/Snail with TNFα/NFκB May Facilitate the Tumor-Stroma Interaction in the EMT Process and Colorectal Cancer Prognosis.

Prognostic Role of Tenascin-C for Cancer Outcome: A Meta-Analysis.